Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
Theodore C. Tarver(University of California, San Francisco), Catherine C. Smith(University of California, San Francisco)
Cited by 76
Related Papers
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745
Travel-associated infection presenting in Europe (2008–12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation
|The Lancet Infectious Diseases|2014|248
Crenolanib is a selective type I pan-FLT3 inhibitor
|Proceedings of the National Academy of Sciences|2014|211
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML
|Cell Reports Medicine|2023|11
Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2025|1